Enterprise Value

5.355B

Cash

963.3M

Avg Qtr Burn

N/A

Short % of Float

3.75%

Insider Ownership

2.17%

Institutional Own.

89.14%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CABOMETYX (cabozantinib) Details
Solid tumor/s, Renal cell carcinoma, Cancer

Approved

Quarterly sales

Approved

Quarterly sales

COMETRIQ (cabozantinib) Details
Metastatic MTC (Medullary Thyroid Cancer)

Approved

Quarterly sales

Zanzalintinib Details
Solid tumor/s, Kidney cancer, Renal cell carcinoma

Phase 3

Data readout

Phase 3

Data readout

CABOMETYX (cabozantinib) + atezolizumab Details
Cancer, Solid tumor/s, Castration-resistant prostate cancer

Phase 3

Update

CABOMETYX (cabozantinib) Details
Cancer, Pancreatic cancer

Phase 3

Update

Zanzalintinib + Pembrolizumab Details
Cancer, Head and neck squamous cell carcinoma

Phase 2/3

Data readout

Zanzalintinib + AB521 Details
Cancer, Kidney cancer, Renal cell carcinoma

Phase 1/2

Data readout

Zanzalintinib Details
Solid tumor/s, Cancer

Phase 1b

Data readout

Zanzalintinib +/- atezolizumab Details
Solid tumor/s, Carcinoma , Cancer

Phase 1b

Update

Phase 1

Update